Beta-blocker use and COPD mortality: a systematic review and meta-analysis

BMC Pulmonary Medicine

Volumn 12, Issue , 2012, Pages

  Etminan, Mahyar ^a,b,c   Jafari, Siavash ^c   Carleton, Bruce ^a,b,c   FitzGerald, John M ^c  

^a PROVINCIAL HEALTH SERVICES AUTHORITY   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Beta blockers; COPD; Mortality

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

ARTICLE; CAUSE OF DEATH; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE ASSOCIATION; DRUG EFFECT; HUMAN; META ANALYSIS; PUBLISHING; RETROSPECTIVE STUDY; RISK FACTOR; SYSTEMATIC REVIEW;

ADRENERGIC BETA-ANTAGONISTS; CARDIOVASCULAR DISEASES; COMORBIDITY; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TREATMENT OUTCOME;

EID: 84865651768     PISSN: None     EISSN: 14712466     Source Type: Journal    
DOI: 10.1186/1471-2466-12-48     Document Type: Article

References (23)

1. Lechat P, Packer M, Chalon S, Cucherat M, Arab T, Boissel JP. Clinical effects of beta-adrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebo-controlled, randomised trials. Circulation 1998, 98:1184-1191. 10.1161/01.CIR.98.12.1184, 9743509.
2. Hjalmarson A, Elmfeldt D, Herlitz J, Holmberg S, Málek I, Nyberg G, Rydén L, Swedberg K, Vedin A, Waagstein F, Waldenström A, Waldenström J, Wedel H, Wilhelmsen L, Wilhelmsson C. Effect on mortality of metoprolol in acute myocardial infarction: a double-blind randomised trial. Lancet 1981, 2:823-827.
3. Hurd S. The impact of COPD on lung health worldwide: epidemiology and incidence. Chest 2000, 117:1S-4S. 10.1378/chest.117.2_suppl.1S, 10673465.
4. Salpeter SR, Ormiston TM, Salpeter EE. Cardioselective beta-blockers in patients with reactive airway disease: a meta-analysis. Cochrane Database Syst Rev 2005, 19:CD003566.
5. Dransfield MT, Rowe SM, Johnson JE, Bailey WC, Gerald LB. Use of beta blockers and the risk of death in hospitalised patients with acute exacerbations of COPD. Thorax 2008, 63:301-305. 10.1136/thx.2007.081893, 17951276.
6. Au DH, Bryson CL, Fan VS, Udris EM, Curtis JR, McDonell MB, Fihn SD. Beta-blockers as single-agent therapy for hypertension and the risk of mortality among patients with chronic obstructive pulmonary disease. Am J Med 2004, 117:925-931. 10.1016/j.amjmed.2004.07.043, 15629731.
7. Anderson JL, Adams CD, Antman EM. 2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American college of cardiology foundation/American heart association task force on practice guidelines. Circulation 2011, 12318:e426-e579.
8. Short PM, Lipworth SI, Elder DH, Schembri S, Lipworth BJ. Effect of beta blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study. BMJ 2011,
9. Rutten FH, Zuithoff NP, Hak E, Grobbee DE, Hoes AW. Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Intern Med 2010, 170:880-887. 10.1001/archinternmed.2010.112, 20498416.
10. Wang R, Miura T, Harada N, Kametani R. Pleiotropic effects of the beta-adrenoceptor blocker carvedilol on calcium regulation during oxidative stress-induced apoptosis in cardiomyocytes. J Pharmacol Exp Ther 2006, 318:45-52. 10.1124/jpet.105.099903, 16611853.
11. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 1998, 339:489-497. 10.1056/NEJM199808203390801, 9709041.
12. Staszewsky L, Wong M, Masson S, Barlera S, Carretta E, Maggioni AP, Anand IS, Cohn JN, Tognoni G, Latini R. Clinical, neurohormonal, and inflammatory markers and overall prognostic role of chronic obstructive pulmonary disease in patients with heart failure: data from the Val-HeFT heart failure trial. J Card Fail 2007, 13:797-804. 10.1016/j.cardfail.2007.07.012, 18068611.
13. van Gestel YR, Hoeks SE, Sin DD, Welten GM, Schouten O, Witteveen HJ, Simsek C, Stam H, Mertens FW, Bax JJ, van Domburg RT, Poldermans D. Impact of cardioselective beta-blockers on mortality in patients with chronic obstructive pulmonary disease and atherosclerosis. Am J Respir Crit Care Med 2008, 178:695-700. 10.1164/rccm.200803-384OC, 18565952.
14. Chen J, Radford MJ, Wang Y, Marciniak TA, Krumholz HM. Effectiveness of beta-blocker therapy after acute myocardial infarction in elderly patients with chronic obstructive pulmonary disease or asthma. J Am Coll Cardiol 2001, 37:1950-1956. 10.1016/S0735-1097(01)01225-6, 11401137.
15. Hawkins NM, Huang Z, Pieper KS, Solomon SD, Kober L, Velazquez EJ, Swedberg K, Pfeffer MA, McMurray JJ, Maggioni AP. Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the valsartan in acute myocardial infarction trial (VALIANT). Eur J Heart Fail 2009, 11:292-298. 10.1093/eurjhf/hfp001, 2645058, 19176539.
16. Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-blocker use in patients with reversible airway disease (Cochrane Review). Cochrane Database Syst Rev 2001, (2).
17. Au DH, Udris EM, Curtis JR, McDonell MB, Fihn SD. Association between chronic heart failure and inhaled beta-2-adrenoceptor agonists. Am Heart J 2004, 148:915-920. 10.1016/j.ahj.2004.03.048, 15523327.
18. Sengstock DM, Obeidat O, Pasnoori V, Mehra P, Sandberg KR, McCullough PA. Asthma, beta-agonists, and development of congestive heart failure: results of the ABCHF study. J Card Fail 2002, 8:232-238. 10.1054/jcaf.2002.127771, 12397571.
19. Heindl S, Lehnert M, Criee CP, Hasenfuss G, Andreas S. Marked sympathetic activation in patients with chronic respiratory failure. Am J Respir Crit Care Med 2001, 164:597-660.
20. Suissa S. Immeasurable time bias in observational studies of drug effects on mortality. Am J Epidemiol 2008, 168:329-335. 10.1093/aje/kwn135, 18515793.
21. Mancini GB, Etminan M, Zhang B, Levesque LE, FitzGerald JM, Brophy JM. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol 2006, 47:2554-2560. 10.1016/j.jacc.2006.04.039, 16781387.
22. Lawes CM, Thornley S, Young R, Hopkins R, Marshall R, Chan WC, Jackson G. Statin use in COPD patients is associated with a reduction in mortality: a national cohort study. Prim Care Respir J 2012, 21:35-40. 10.4104/pcrj.2011.00095, 22218819.
23. Simvastatin therapy for moderate and severe COPD (STSTCOPE) United States National Institute of Health, http://clinicaltrials.gov/ct2/show/NCT01061671 (Accessed August 31,2012).